Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the mayo phase II consortium and the cancer therapeutics research group (MC1079)

B. B Y Ma, B. C. Goh, W. T. Lim, E. P. Hui, E. H. Tan, G. De Lima Lopes, K. W. Lo, L. Li, H. Loong, N. R. Foster, C. Erlichman, A. D. King, M. K M Kam, S. F. Leung, K. C. Chan, A. T C Chan

Research output: Contribution to journalArticle

Abstract

Background This study investigated the activity of MK-2206, an AKT inhibitor, in metastatic or recurrent nasopharyngeal carcinoma (NPC). Method Oral MK-2206 at a dose of 200 mg was administered on days 1, 8, 15 and 22 of a 28-day cycle until progression. Plasma EBV DNA clearance during the first month of treatment was measured, and archived tumors were analyzed for the expression of AKT and PIK3CA mutation and PIK3CA amplification. The dual primary endpoint was objective response rate and 6-month progression-free survival (PFS) rate. Results 21 patients were enrolled and one patient achieved a partial response (5 %) and 11 had stable disease (52 %), with a median PFS of 3.5 months (95 % confidence interval, CI: 0.9-7.3). The 6-month PFS rate was 43 % (95 % CI: 22-66 %) and the median OS was 10 months (95 % CI: 5.9 months-not reached). Seven patients (33 %) experienced grade 3 toxicities which could be related to MK-2206. Macular-papular rash was the most common (n = 6), followed by hyperglycemia (n = 2) and fatigue (n = 1). In the 12 tumor samples analyzed, PIK3CA amplification was detected in one patient's primary NPC, who had SD lasting over 12 months. Patients with decreasing EBV DNA values over time were more likely to be alive and progression-free for at least 6 months than those without a decrease (p = 0.001). Conclusion The study was terminated due to the limited activity observed in this heavily pre-treated group of patients. Further studies are needed to elucidate the optimal way of selecting patients for AKT inhibitors.

Original languageEnglish (US)
Pages (from-to)985-991
Number of pages7
JournalInvestigational New Drugs
Volume33
Issue number4
DOIs
StatePublished - Aug 1 2015
Externally publishedYes

Fingerprint

Therapeutic Human Experimentation
Neoplasms
Disease-Free Survival
Human Herpesvirus 4
Survival Rate
DNA
Nasopharyngeal carcinoma
MK 2206
Exanthema
Hyperglycemia
Fatigue
Confidence Intervals
Mutation

Keywords

  • AKT inhibitor
  • MK2206
  • Nasopharyngeal carcinoma
  • PIK3CA

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Oncology

Cite this

Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the mayo phase II consortium and the cancer therapeutics research group (MC1079). / Ma, B. B Y; Goh, B. C.; Lim, W. T.; Hui, E. P.; Tan, E. H.; Lopes, G. De Lima; Lo, K. W.; Li, L.; Loong, H.; Foster, N. R.; Erlichman, C.; King, A. D.; Kam, M. K M; Leung, S. F.; Chan, K. C.; Chan, A. T C.

In: Investigational New Drugs, Vol. 33, No. 4, 01.08.2015, p. 985-991.

Research output: Contribution to journalArticle

Ma, BBY, Goh, BC, Lim, WT, Hui, EP, Tan, EH, Lopes, GDL, Lo, KW, Li, L, Loong, H, Foster, NR, Erlichman, C, King, AD, Kam, MKM, Leung, SF, Chan, KC & Chan, ATC 2015, 'Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the mayo phase II consortium and the cancer therapeutics research group (MC1079)', Investigational New Drugs, vol. 33, no. 4, pp. 985-991. https://doi.org/10.1007/s10637-015-0264-0
Ma, B. B Y ; Goh, B. C. ; Lim, W. T. ; Hui, E. P. ; Tan, E. H. ; Lopes, G. De Lima ; Lo, K. W. ; Li, L. ; Loong, H. ; Foster, N. R. ; Erlichman, C. ; King, A. D. ; Kam, M. K M ; Leung, S. F. ; Chan, K. C. ; Chan, A. T C. / Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the mayo phase II consortium and the cancer therapeutics research group (MC1079). In: Investigational New Drugs. 2015 ; Vol. 33, No. 4. pp. 985-991.
@article{57d6e3fb0f7840a69b2b9d1ed269c449,
title = "Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the mayo phase II consortium and the cancer therapeutics research group (MC1079)",
abstract = "Background This study investigated the activity of MK-2206, an AKT inhibitor, in metastatic or recurrent nasopharyngeal carcinoma (NPC). Method Oral MK-2206 at a dose of 200 mg was administered on days 1, 8, 15 and 22 of a 28-day cycle until progression. Plasma EBV DNA clearance during the first month of treatment was measured, and archived tumors were analyzed for the expression of AKT and PIK3CA mutation and PIK3CA amplification. The dual primary endpoint was objective response rate and 6-month progression-free survival (PFS) rate. Results 21 patients were enrolled and one patient achieved a partial response (5 {\%}) and 11 had stable disease (52 {\%}), with a median PFS of 3.5 months (95 {\%} confidence interval, CI: 0.9-7.3). The 6-month PFS rate was 43 {\%} (95 {\%} CI: 22-66 {\%}) and the median OS was 10 months (95 {\%} CI: 5.9 months-not reached). Seven patients (33 {\%}) experienced grade 3 toxicities which could be related to MK-2206. Macular-papular rash was the most common (n = 6), followed by hyperglycemia (n = 2) and fatigue (n = 1). In the 12 tumor samples analyzed, PIK3CA amplification was detected in one patient's primary NPC, who had SD lasting over 12 months. Patients with decreasing EBV DNA values over time were more likely to be alive and progression-free for at least 6 months than those without a decrease (p = 0.001). Conclusion The study was terminated due to the limited activity observed in this heavily pre-treated group of patients. Further studies are needed to elucidate the optimal way of selecting patients for AKT inhibitors.",
keywords = "AKT inhibitor, MK2206, Nasopharyngeal carcinoma, PIK3CA",
author = "Ma, {B. B Y} and Goh, {B. C.} and Lim, {W. T.} and Hui, {E. P.} and Tan, {E. H.} and Lopes, {G. De Lima} and Lo, {K. W.} and L. Li and H. Loong and Foster, {N. R.} and C. Erlichman and King, {A. D.} and Kam, {M. K M} and Leung, {S. F.} and Chan, {K. C.} and Chan, {A. T C}",
year = "2015",
month = "8",
day = "1",
doi = "10.1007/s10637-015-0264-0",
language = "English (US)",
volume = "33",
pages = "985--991",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "4",

}

TY - JOUR

T1 - Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the mayo phase II consortium and the cancer therapeutics research group (MC1079)

AU - Ma, B. B Y

AU - Goh, B. C.

AU - Lim, W. T.

AU - Hui, E. P.

AU - Tan, E. H.

AU - Lopes, G. De Lima

AU - Lo, K. W.

AU - Li, L.

AU - Loong, H.

AU - Foster, N. R.

AU - Erlichman, C.

AU - King, A. D.

AU - Kam, M. K M

AU - Leung, S. F.

AU - Chan, K. C.

AU - Chan, A. T C

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Background This study investigated the activity of MK-2206, an AKT inhibitor, in metastatic or recurrent nasopharyngeal carcinoma (NPC). Method Oral MK-2206 at a dose of 200 mg was administered on days 1, 8, 15 and 22 of a 28-day cycle until progression. Plasma EBV DNA clearance during the first month of treatment was measured, and archived tumors were analyzed for the expression of AKT and PIK3CA mutation and PIK3CA amplification. The dual primary endpoint was objective response rate and 6-month progression-free survival (PFS) rate. Results 21 patients were enrolled and one patient achieved a partial response (5 %) and 11 had stable disease (52 %), with a median PFS of 3.5 months (95 % confidence interval, CI: 0.9-7.3). The 6-month PFS rate was 43 % (95 % CI: 22-66 %) and the median OS was 10 months (95 % CI: 5.9 months-not reached). Seven patients (33 %) experienced grade 3 toxicities which could be related to MK-2206. Macular-papular rash was the most common (n = 6), followed by hyperglycemia (n = 2) and fatigue (n = 1). In the 12 tumor samples analyzed, PIK3CA amplification was detected in one patient's primary NPC, who had SD lasting over 12 months. Patients with decreasing EBV DNA values over time were more likely to be alive and progression-free for at least 6 months than those without a decrease (p = 0.001). Conclusion The study was terminated due to the limited activity observed in this heavily pre-treated group of patients. Further studies are needed to elucidate the optimal way of selecting patients for AKT inhibitors.

AB - Background This study investigated the activity of MK-2206, an AKT inhibitor, in metastatic or recurrent nasopharyngeal carcinoma (NPC). Method Oral MK-2206 at a dose of 200 mg was administered on days 1, 8, 15 and 22 of a 28-day cycle until progression. Plasma EBV DNA clearance during the first month of treatment was measured, and archived tumors were analyzed for the expression of AKT and PIK3CA mutation and PIK3CA amplification. The dual primary endpoint was objective response rate and 6-month progression-free survival (PFS) rate. Results 21 patients were enrolled and one patient achieved a partial response (5 %) and 11 had stable disease (52 %), with a median PFS of 3.5 months (95 % confidence interval, CI: 0.9-7.3). The 6-month PFS rate was 43 % (95 % CI: 22-66 %) and the median OS was 10 months (95 % CI: 5.9 months-not reached). Seven patients (33 %) experienced grade 3 toxicities which could be related to MK-2206. Macular-papular rash was the most common (n = 6), followed by hyperglycemia (n = 2) and fatigue (n = 1). In the 12 tumor samples analyzed, PIK3CA amplification was detected in one patient's primary NPC, who had SD lasting over 12 months. Patients with decreasing EBV DNA values over time were more likely to be alive and progression-free for at least 6 months than those without a decrease (p = 0.001). Conclusion The study was terminated due to the limited activity observed in this heavily pre-treated group of patients. Further studies are needed to elucidate the optimal way of selecting patients for AKT inhibitors.

KW - AKT inhibitor

KW - MK2206

KW - Nasopharyngeal carcinoma

KW - PIK3CA

UR - http://www.scopus.com/inward/record.url?scp=84957439058&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957439058&partnerID=8YFLogxK

U2 - 10.1007/s10637-015-0264-0

DO - 10.1007/s10637-015-0264-0

M3 - Article

C2 - 26084990

AN - SCOPUS:84957439058

VL - 33

SP - 985

EP - 991

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 4

ER -